In a flurry of meetings with federal officials, drug industry and provider groups are making a final push to influence [...] …
Category: Providers
Oregon has enacted a new law granting health centers and certain grantees more flexibility in how they report 340B claims [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Provider groups are sharply criticizing the newly enacted, GOP-backed budget reconciliation bill, warning that its more than $1 trillion in [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
California state senators have amended new provider reporting and auditing requirements onto a bill barring drugmakers from placing 340B contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The New York State Assembly recently honored longtime pharmacy leader and 340B advocate Mark Malahosky with a resolution commemorating his [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Hospital and health care provider advocates this week once again urged federal lawmakers to reject a controversial GOP-backed reconciliation plan [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two large drug companies this week filed federal lawsuits seeking to strike down Oklahoma’s new law prohibiting drugmaker 340B contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A major brand-name drug industry trade group recently filed the first federal lawsuit challenging Vermont’s newly enacted 340B contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Kentucky’s Medicaid program this week launched a new 340B claims submission process that enables covered entities to carve in Medicaid [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Johnson & Johnson (J&J) has formally appealed a federal judge’s ruling that drugmakers cannot unilaterally implement a 340B rebate model—a [...] …